Abstract Number: 1021 • 2019 ACR/ARP Annual Meeting
Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice
Background/Purpose: Many systemic lupus erythematosus patients display a type I interferon (IFN) signature, and IFNα levels and gene signatures have been positively correlated with disease…Abstract Number: 1028 • 2019 ACR/ARP Annual Meeting
Lupus Auto-antibodies Act as Positive Allosteric Modulators at GluN2A-containing NMDA Receptors to Induce Excitotoxicity and Spatial Memory Deficits
Background/Purpose: Patients with Systemic lupus erythematosus (SLE) experience various peripheral and central nervous system manifestations including spatial memory impairment. A subset of auto-antibodies (DNRAbs) cross-react…Abstract Number: 2159 • 2019 ACR/ARP Annual Meeting
Pachymeningitis in Rheumatic Disease
Background/Purpose: Pachymeningitis is a rare complication of rheumatic disease. Patients present with hearing loss or other neurologic complications. Diagnosis is made by thickening of dura…Abstract Number: 2992 • 2014 ACR/ARHP Annual Meeting
Usefulness of Diagnostic Biomarker for Neuropsychiatric Systemic Lupus Erythematosus By Anti-Microtubule Associated Protein 2 Antibody in Cerebrospinal Fluid
Background/Purpose: Microtubule associated protein-2 (MAP-2) is found exclusively in nerve cells. MAP-2 has been shown to stabilize microtubules by binding to the outer surface and…Abstract Number: 2661 • 2014 ACR/ARHP Annual Meeting
Serum Neuronal Biomarkers and Brain Atrophy in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose We aimedto investigate the association of serum biomarkers and regional and diffuse brain atrophy in cSLE. Methods We included consecutive cSLE patients (disease-onset before…